近日， 冰晶智能宣布完成数千万人民币 A 轮融资 。本轮投资方为 江夏科投 、 盛科智造 ， 天超资本 、 大桉资本 （DAION CAPITAL）担任本轮财务顾问。公司表示，本轮融资资金将主要用于生产基地建设、运营投入及流动资金补充。 # ICE 市场前景及概况 心腔内超声（ ICE ）是一种 将相控阵超声成像和心脏导管术进行融合的经皮血管介入超声影像技术 。 ICE 具有 实时超声成像 、 不受成像窗限制 以及 良好耐受性 等优点。在手术实施过程中只需局部麻醉，调弯操作灵活，超 声影像全程可视，帮助临床医生获取心腔内的解剖结构，实时监测术中并发症，并进行多普勒血流评估。 近年来，随着结构性心脏病和心律失常疾病介入诊疗技术的快速发展，对术中影像的要求越来越高，随着 ICE 技术的适用范 围越来越广， ICE 导管逐渐成为心脏介入医生的 " 黄金眼 " 。 产品采用了业 内 首创的新一代声能转换系统 ，可有效提升信号采集、传输效率及图像清晰度；同时，HD-ICE系统采用了 国产首创的高清心脏图像专用处理系统 ，运用业内最新的算法技术，有更快的成像速度，从而可以满足更多的临床需求。 ▲公司相关产品线 在临床层面 ...

Core Insights - The article discusses the approval of 75 innovative medical devices in China by December 31, 2025, highlighting a shift towards products that follow verifiable clinical pathways and replicable product systems [2]. Overview - Domestic products: 63 items - Imported products: 12 items - Domestic medical devices account for over 80% of the total, with imported products mainly in high-complexity and high-clinical-barrier segments, reflecting "filling-type innovation" [3]. Technical Field Distribution - The cardiovascular field remains the "main battlefield," driven by high disease prevalence and continuous evolution in intervention methods and operational techniques [5]. - Other fields like ophthalmology, neurology, and oncology, while fewer in number, exhibit high technical barriers and clear clinical pathways, characterized by a "few but refined" approach [7]. Approval Rhythm - The approval of innovative devices shows a clear "rhythm" throughout the year, indicating a shift from "periodic concentration release" to "normalized operation" in the innovation channel [9]. - Peaks in approvals were noted in April and December, with other months maintaining a stable release rhythm [11]. Regional Distribution - Innovative medical devices are highly concentrated in regions with dense industrial and research resources, indicating that regional innovation ecosystems (universities, hospitals, capital, manufacturing capabilities) are crucial for the development of innovative devices [12]. Trend Judgments - Three clear trends for innovative medical devices in 2025: - The innovation threshold is shifting from "technically feasible" to "clinically applicable" [14]. - Single-point innovations are insufficient for long-term value; systemic solutions are becoming mainstream [15]. - The evaluation logic for innovation is increasingly focusing on real-world value, with clinical applicability, stability, and learning curves becoming as important as technological advancement [16].

Core Viewpoint - The article emphasizes that cranioplasty is not merely a "patch surgery" but a complex integration of structure and morphology, where the final aesthetic outcome and long-term stability are crucial for patient satisfaction [1][3]. Group 1: Clinical Pain Points - Cranioplasty is often viewed as a "structural repair," but it involves a comprehensive challenge related to geometry, mechanics, and long-term stability [2]. - Irregular defect shapes can lead to "secondary asymmetry" during surgery, as manual adjustments to materials often fail to ensure edge continuity [2]. - Key contour areas are highly sensitive to "millimeter-level errors," which can affect tactile and visual outcomes for patients [2][4]. - Long-term stability is a core indicator of treatment efficacy, with factors like material absorption, thermal expansion, and mechanical stability influencing the durability of the reconstruction [5]. Group 2: Material System - Polyether ether ketone (PEEK) is increasingly chosen for craniomaxillofacial reconstruction due to its long-term clinical validation and alignment with cranioplasty needs [6]. - PEEK's elastic modulus closely matches that of cortical bone, allowing for a more natural edge transition and tactile experience for patients [6]. - The material is non-absorbent and corrosion-resistant, maintaining shape stability over time, which is critical for preventing "secondary changes" in appearance [6]. - PEEK exhibits excellent imaging compatibility, producing minimal artifacts in CT/MRI scans, which is vital for long-term follow-up of patients [7]. - The material possesses sufficient mechanical strength to provide predictable structural support, especially in large defects or load-bearing areas [7]. Group 3: Product Features - The newly approved localized patient-matched PEEK cranioplasty system builds on an established engineering framework, utilizing high-quality materials with over 20 years of clinical experience [9]. - The system allows for anatomical-level restoration of curvature, moving from manual sculpting to digital modeling, which resolves many shape-related issues preoperatively [11]. - The design includes a gradual thinning transition at the defect edges, enhancing tactile and aesthetic outcomes, which is difficult to achieve through manual methods [12]. - Surface roughness is controlled to balance early stability and long-term safety, ensuring a smooth interface with surrounding tissues [14]. - The layout of fixation holes is designed to meet both mechanical requirements and surgical habits, facilitating predictable surgical actions [14]. Group 4: Localization Significance - The localization of the PEEK cranioplasty system enhances accessibility to high-quality reconstruction options, allowing for clearer execution conditions in clinical settings [15]. - A defined delivery schedule supports surgical planning, making personalized implants a routine choice rather than an exception [16]. - Local design teams ensure accurate implementation of design intentions, improving interface stability and reducing risks associated with micro-movements [18]. - The production system is not a simple replication but a transfer of existing international standards, ensuring consistent quality across different regions [21].

对医疗器械公司来说，市场部的核心战场往往在会场上：新品亮相、学术教育、专家共识、渠道触达。 2026年已至，哪些大会必须参加？哪些论坛值得布局？ 思宇MedTech整理了39场医疗器械相关会议，供市场部参考（更多大会信息还在陆续发布中，我们后续会有更完整 的版本） 2026年生物医学工程、智能感知技术与医学应用国际学术会议 会议时间：2026年1月9–11日 会议地点：沈阳 第十届神经学与神经外科国际研讨会 会议时间：2026年1月9–11日 会议地点：三亚 2026年西湖心血管病临床进展研究大会 会议时间：2026年1月16–17日 会议地点：杭州 2026年3月 第三届全球生物医药大会 会议时间：2026年3月19日 会议地点：北京中关村会议中心 会议时间：2026年3月21–23日 会议地点：厦门 2026医学装备展览会 会议时间：2026年3月26–29日 会议地点： 重庆 2026年4月 CMEF 春季（中国国际医疗器械博览会） 会议时间：2026年4月9–12日 会议地点：上海 "第二十六届国际眼科学学术会议"与"第二十六届国际视光学学术会议"（COOC 2026） 会议时间：2026年4月9–1 ...

# 一个规模巨 大 、但变化缓慢的器械赛道 透析是终末期肾病患者不可替代的长期治疗方式，也是医疗器械领域中规模最大的单一治疗场景之一。但 与其市场体量并不匹配的是，该领域在治疗模式和系统效率上的变化相对有限。 在国内，透析治疗仍高度依赖中心化医疗机构，患者需长期、高频往返医院完成治疗。这一模式在保障安 全性的同时，也带来了明显的现实问题：患者时间与体力负担沉重，基层地区可及性不足，医疗机构在医 保控费和耗材集采背景下面临持续运营压力。 在此基础上，透析治疗对患者生存质量的改善空间也相对有限，使得这一领域逐渐呈现出 "刚需、高频、但 系统效率偏低" 的特征。 近日， 上海心光生物医药有限责任公司 （以下简称"心光生物"）宣布完成 数千万元A1轮融资 。本轮融资 由国际知名机构领投，老股东 兴富资本 跟投，凯乘资本担任长期财务顾问。公司表示，募集资金将主要用 于再生型腹膜透析产品的型式检验、临床试验及注册申报等关键节点。 在当前医疗器械投资更加关注 "是否解决真实系统性问题" 的背景下，心光生物所切入的透析赛道，并非高 速变化的热门领域，却长期存在结构性矛盾。本轮融资，更多体现的是资本对透析治疗模式调整可能性的 ...

Core Insights - The core viewpoint of the article is that the market for laparoscopic surgical robots in China is experiencing a structural shift, with domestic brands, particularly Jingfeng Medical, gaining significant traction against the dominant Da Vinci system, indicating a growing competitive landscape [3][4][20]. Group 1: Overall Market Landscape - In 2025, the laparoscopic surgical robot market in China continued to show steady growth despite overall pressure in the medical device market [3]. - Da Vinci remains the market leader, but domestic brands have begun to establish a foothold, with eight domestic manufacturers achieving public bidding success [3][4]. - Domestic brands collectively won 47 bids, accounting for approximately 52% of the total, with Jingfeng Medical leading with 16 bids (34% of the total) [3][4]. Group 2: Manufacturer Performance - The top domestic manufacturers include Jingfeng Medical, Weichuang Robotics, and Sizhe Rui, which are emerging as significant players in the market [4]. - The bidding data indicates a clear differentiation among domestic manufacturers in terms of bidding quantity and pricing, reflecting varying stages of development and capabilities [5][9]. Group 3: Bidding Quantity and Price Structure - In 2025, the total number of bids and the total bid amounts show a concentrated structure, with Jingfeng Medical, Weichuang Robotics, and Sizhe Rui significantly outperforming other manufacturers [9]. - The average bid price for Da Vinci was 1,817,000 RMB, while Jingfeng Medical's average was 1,453,000 RMB, indicating a competitive pricing strategy among domestic brands [6][9]. Group 4: Hospital Selection Behavior - The majority of bids were awarded to tertiary hospitals, indicating that these institutions are the primary market for laparoscopic surgical robots, reflecting a judgment of capability rather than policy-driven procurement [11][14]. - There is a noticeable trend of hospitals making multiple bids within the same year, suggesting a shift from merely introducing equipment to expanding its use based on real-world experience [15][16]. - Domestic manufacturers are increasingly entering various levels of hospitals, with successful bids in multiple regions, indicating a move towards broader market acceptance [16][20]. Group 5: Conclusion - The data from 2025 indicates a significant transition in the market, where continuous bidding and cross-regional bids are becoming new benchmarks for success, moving beyond initial equipment introduction to sustained usage [17][20].

Core Viewpoint - The article emphasizes the importance of the "2026 Global Health Industry Innovation Conference" to promote high-quality development in the health sector, driven by innovative technologies like AI and big data, aligning with national strategies for health and innovation [1][3]. Group 1: Conference Overview - The conference titled "汇智·无界" will take place on January 18, 2026, at the Zhongguancun International Innovation Center in Beijing [1][13]. - It aims to gather experts from various fields, including government officials, academicians, and industry representatives, to discuss the future of the health industry and explore innovative solutions [3][13]. Group 2: Key Themes and Topics - The conference will focus on the transformative impact of digital technologies on healthcare, including precision diagnostics, intelligent treatment, and comprehensive health management [3]. - Various parallel forums will address topics such as AI-driven medical services, innovations in urology, and the integration of traditional Chinese medicine with modern technology [15][17]. Group 3: Notable Speakers - Distinguished speakers include academicians from the Chinese Academy of Engineering and the Chinese Academy of Sciences, as well as leaders from major healthcare institutions and pharmaceutical companies [6][19]. - Keynote presentations will cover topics like AI in clinical research, intelligent medical imaging, and the development of new healthcare ecosystems [17][19]. Group 4: Supporting Organizations - The conference is supported by various institutions, including the Beijing Health Commission and several prominent hospitals and universities, highlighting a collaborative approach to healthcare innovation [13][21]. - Strategic partners include major pharmaceutical companies and technology firms, indicating a strong industry backing for the event [13][21].

为持续追踪全球医疗器械领域的真实创新进展， 思宇 MedTech自 2023 年起启动 "全球医疗科技榜单与奖项"（Global MedTech Awards） 评选体系 ，旨在从产业视 角出发，识别并记录那些在技术创新、产业协同、组织能力建设及长期投入等方面，对医疗科技产业发展产生积极影响的企业。 在 2023 年、2024 年及 2025 年上半年，思宇 MedTech 已持续发布多项榜单与奖项，系统呈现医疗科技领域的重要进展。基于对年度产业动态的持续跟踪与观察， 我们于 2025 年底进一步聚焦在本年度内快速成长、展现出明确创新潜力与产业价值的新锐企业。 本次评选不以企业规模或市场声量为导向，而是围绕三个核心维度展开： 本次补录的「2025 全球医疗科技新锐奖」，共遴选 9 家医疗器械企业 ，覆盖治疗设备、植入器械、诊断器械与数字医疗器械等不同技术方向。这些企业的共同特 征并非"技术炫目"，而是对临床路径的重新理解与重构。 注意：评委会只能从提交材料的企业中选择，每年会发布2次征集通知，请创新型企业积极申报。 海外医疗器械企业（5 家） （排名不分先后） Kidney Beam（英国） 技术创新性和解决 ...

Core Viewpoint - The medical device sector is becoming one of the most certain and continuously evolving segments within the healthcare system, with ten related markets entering an acceleration phase due to clinical demand, payment logic, and technological maturity [2]. Summary by Relevant Sections Accelerating Medical Device Markets - Ten medical device markets are identified as entering an acceleration phase, indicating a significant shift in how medical services are provided, executed, and managed [2][3]. Market Growth Projections - **Disposable Endoscopes Market**: Expected to grow from $840 million in 2024 to $2.67 billion by 2030, with a CAGR of 22.9% [5]. - **Dental 3D Printing Market**: Projected to increase from $3.4 billion in 2024 to $10.06 billion by 2030, with a CAGR of 20.5% [6]. - **Surgical Imaging Market**: Anticipated to rise from $3.9 billion in 2023 to $12.2 billion by 2030, with a CAGR of 17.6% [7]. - **Surgical Robots Market**: Expected to grow from $9.6 billion in 2023 to $23.7 billion by 2029, with a CAGR of 16.5% [8]. - **Medical Robots Market**: Projected to increase from $13.8 billion in 2023 to $33.8 billion by 2029, with a CAGR of 16.1% [9]. - **Minimally Invasive Surgery Market**: Expected to grow from $81.65 billion in 2024 to $199.3 billion by 2030, with a CAGR of 16.1% [10]. - **Surgical Instrument Tracking System Market**: Anticipated to rise from $31.4 million in 2024 to $75.1 million by 2030, with a CAGR of 15.2% [12]. - **Autoinjectors Market**: Expected to grow from $1.08 billion in 2024 to $3.02 billion by 2030, with a CAGR of 13.6% [14]. - **Medical Aesthetics Market**: Projected to increase from $17.16 billion in 2024 to $35.32 billion by 2030, with a CAGR of 12.8% [15]. - **Diabetes Care Devices Market**: Expected to grow from $34.3 billion in 2025 to $61.2 billion by 2030, with a CAGR of 12.3% [16]. Common Directions Behind Growth - The ten markets are not isolated; they point towards several clear trends: - Medical services are becoming "de-experienced," with devices taking over tasks previously reliant on personal experience to reduce uncertainty [18]. - Efficiency is becoming a critical consideration in payment and procurement, driving growth in imaging, tracking, and disposable products [19]. - Minimally invasive and low-invasion procedures are becoming the default assumption rather than an optional choice [19]. - Healthcare is transitioning from "single-point devices" to "systematic operations," with platform, modular, and process capabilities becoming the new core of competition [20]. Reasons for Current Acceleration - The changes are not sudden but are the result of the convergence of technological maturity, shifts in payment logic, and structural labor shortages in healthcare, leading to a focus on devices that can change operational methods [21].

Core Viewpoint - Solventum's acquisition of Acera Surgical marks a significant step in its strategic shift from asset restructuring to active expansion in the advanced wound care sector, with a total potential consideration of up to $850 million [1][3][12] Group 1: Acquisition Details - Solventum will pay $725 million in cash for the base acquisition, with an additional performance-related consideration of up to $125 million, bringing the total potential consideration to $850 million (approximately 6 billion RMB) [1] - Acera Surgical will be integrated into Solventum's business structure, with its synthetic tissue matrix products added to Solventum's existing wound care solutions [1][3] Group 2: Strategic Rationale - The acquisition is seen as a targeted enhancement in advanced wound care, addressing Solventum's need to strengthen its capabilities in complex wound repair and tissue regeneration [3][8] - Solventum's existing global sales network and market access capabilities will facilitate the rapid commercialization of Acera's core product, Restrata®, which has already undergone technical and clinical validation [10] Group 3: Industry Trends - The acquisition reflects a broader structural change in the advanced wound care market, shifting from low-cost consumables to solutions centered on material science and tissue repair [11] - There is a growing trend among large medical enterprises to acquire mature technologies and products through mergers and acquisitions, rather than relying solely on long-term, high-investment research and development [11]